Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 29, 2025
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
GlobeNewswire
·
April 29, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, …
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du Rapport Annuel Form 20-F 2024
GlobeNewswire
·
April 29, 2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 29 avril 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …
The Dealmakers Announces 'Investors Roundtable in Malta' in Strategic Cooperation with FinanceMalta
EIN Presswire
·
April 29, 2025
Connecting global investors with Malta’s key industries to foster cross-border partnerships, innovation, and strategic growth through FinanceMalta's support. DUBAI, UNITED ARAB EMIRATES, April 29, 2025 /EINPresswire.com/ -- The Dealmakers, the …
ISO 13485 Certification – I3CGLOBAL Launches New Strategies for Early Audit Success
EIN Presswire
·
April 29, 2025
Introduces early stage audit readiness solutions to streamline ISO 13485 certification for medical device and IVD companies inline with MDR, IVDR and FDA QMSR CHARLOTTE, NC, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- I3CGLOBAL, a global leader …
Mitolyn Reviews Consumer Reports 2025 - Mitolyn Reviews And Complaints - Mitolyn Weight Loss Supplement - What Is Mitolyn - Does Mitolyn Work - Is Mitolyn Legit or Scam!
GlobeNewswire
·
April 29, 2025
Tallmadge, OH, April 29, 2025 (GLOBE NEWSWIRE) -- (When people look for weight loss supplements, their experiences and real results matter more than advertisements. Mitolyn is gaining attention, and many are asking: Does it really work? Are the results …
Best Steroid for Women for Muscle Growth and Fat Loss 2025 - Top Anabolic Steroids for Female Bodybuilders With Before and After Results - CrazyBulk
GlobeNewswire
·
April 29, 2025
New York City, April 29, 2025 (GLOBE NEWSWIRE) -- Best steroids for women for building muscle and losing fat presented by CrazyBulk Are you a female bodybuilder or athlete looking to take your physique to the next level in 2025? Building muscle and losing …
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
GlobeNewswire
·
April 29, 2025
WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today informed shareholders about several differences between holding shares in Direct Registration System (“DRS”) accounts and holding them …
Global Congenital Hyperinsulinism Treatment Market Set to Surpass USD 201.4 Million by 2035 | FMI
EIN Presswire
·
April 29, 2025
Rising Prevalence of Genetic Disorders, Technological Advances, and Growing Government Support Power the Market Forward NEWARK, DE, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- The global congenital hyperinsulinism treatment market is poised for …
NADP Advocates for Greater Access to Care through Dental Coverage
GlobeNewswire
·
April 29, 2025
DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- The National Association of Dental Plans (NADP) demonstrated its strong commitment to expanding access to dental care during its annual Advocacy in Action (AIA) event, April 2-3 in Washington, D.C. In more than …
Substance use accelerates brain aging through distinct molecular pathways, groundbreaking study reveals
EIN Presswire
·
April 29, 2025
New research from UTHealth Houston reveals that substance use disorders accelerate biological aging in the brain through substance-specific molecular pathways. HOUSTON, TX, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- In a comprehensive Genomic …
Phenylketonuria Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight
GlobeNewswire
·
April 29, 2025
New York, USA, April 29, 2025 (GLOBE NEWSWIRE) -- Phenylketonuria Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight Phenylketonuria, which is characterized by the …
Louw Alberts Psychology Practice Rebrands from Talk It Out to Strengthen Identity
GlobeNewswire
·
April 29, 2025
Centurion, Gauteng, April 29, 2025 (GLOBE NEWSWIRE) -- Louw Alberts Psychology Practice, a renowned counselling practice based in Centurion, South Africa, has officially rebranded from its former name, Talk It Out. This strategic change aims to eliminate …
Global Andersen-Tawil Syndrome Treatment Market Poised for Remarkable Growth, Expected to Reach USD 4.71 Billion by 2035
EIN Presswire
·
April 29, 2025
Andersen-Tawil Syndrome Treatment Market poised for steady growth from 2025 to 2035, driven by advances in genetics, novel therapies, and rising awareness. NEWARK, DE, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- The global andersen-tawil …
Lirum Therapeutics’ LX-101 New Positive Data Selected for Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 29, 2025
New York, NY, April 29, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new positive data on LX-101 against an …
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
GlobeNewswire
·
April 29, 2025
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to develop and manufacture biosimilar, with Sandoz to …
remMD Launches Glow Guide: A Smart Mobility Accessory Designed to Support Safer, Smarter Movement for Aging Adults
GlobeNewswire
·
April 29, 2025
New York, New York, April 29, 2025 (GLOBE NEWSWIRE) -- remMD announces the official launch of Glow Guide, a smart mobility accessory created to make nighttime movement safer and more manageable for individuals using canes, walkers, or wheelchairs. Designed …
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT
GlobeNewswire
·
April 29, 2025
West Palm Beach, April 29, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that effective 4.01pm Eastern Time, on April 28, 2025, (the “Effective Time”), the Company completed a 1 for 10 …
AscellaHealth Honored as Silver Stevie® Award Winner in 2025 American Business Awards®
GlobeNewswire
·
April 29, 2025
BERWYN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, proudly announces it is the winner of a Silver Stevie® Award in the Fastest Growing Company …
Axiom Medical Marks 25 Years of Advancing Workplace Safety and Health at Annual Client Summit
GlobeNewswire
·
April 29, 2025
HOUSTON, TX, April 29, 2025 (GLOBE NEWSWIRE) -- Axiom Medical, a leader in occupational health and workplace injury case management solutions, celebrated 25 years of protecting workers and supporting employers at its 2025 Client Summit. Held in the Houston …
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
GlobeNewswire
·
April 29, 2025
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer …